Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481724 · ClinicalTrials.gov registry record · NA
Gamma-linolenic Acid Supplementation Study
A NA study, sponsored by Virta Health.
- Completed
- Registry status
- NA
- Development phase
- 302
- Enrollment target
NCT04481724 is a NA study that has completed, run by Virta Health. The registered enrollment target is 302 participants.
The verdict
NCT04481724, a NA study, has completed, sponsored by Virta Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 302 participants
- Enrollment target
Study Summary
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT gamma-linolenic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2023-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04481724
The ClinicalTrials.gov registry entry for NCT04481724 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virta Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04481724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04481724 about?
NCT04481724 is a clinical study titled "Gamma-linolenic Acid Supplementation Study". Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight...
What is the current status of trial NCT04481724?
This trial is currently completed. It is a NA study. The enrollment target is 302 participants. The study started on 2020-07-22. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT04481724?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), gamma-linolenic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04481724?
This trial is sponsored by Virta Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.